NCCN 15th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™
Educational Objectives
Following this program, participants should be able to:
Integrate the updates to NCCN Guidelines for acute myeloid leukemia, breast cancer, cervical cancer, colon cancer, esophageal cancer, malignant pleural mesothelioma, multiple myeloma, non-small cell lung cancer, occult primary, and prostate cancer into professional practice
Discuss decision-making regarding chemotherapy in addition to other disease-directed and palliative therapies at end of life
Explain the connection between HPV and the risk of cancer
Discuss the implications of health policy changes for access to and availability of drugs, biologics, devices, and procedures for patients with cancer.
Define the role of clinical evaluative information in the setting of coverage policy, the development of comparative effectiveness paradigms, and of new payor programs.
Describe the utility of molecular testing for identifying carcinomas of unknown primary.
Discuss the data supporting molecular testing of tumors to identify the primary site of disease.
Describe the treatment strategies for treating young adults with cancer
Discuss new advances in the management of CNS metastases
Explain the management of common adverse experiences related to cancer therapy
Summarize the findings of the NCCN Task Forces: Gastrointestinal Stromal Tumors, Transfusion and Iron Overload in Myelodysplastic Syndromes, and Specialty Pharmacy in Oncology – Impact on Patient Care and Practice
These objectives are subject to change as agenda is finalized.